• TCRX is trading at $1.03 (6.8% up) following the announcement of positive initial data from Cohort C of its ALLOHAâ„¢ Phase 1 study evaluating TSC-101.
  • The company reported that 11 of 14 patients dosed had complete donor chimerism within approximately three weeks of receiving the first infusion of TSC-101.
  • This positive clinical update, released on June 22, 2026, could be contributing to the current trading momentum.